Novo Nordisk second best in the world at providing access to medicine

Novo NordiskToday, it was announced that Novo Nordisk ranks second on the 2014 Access to Medicine Index, climbing four places since the 2012 Index. Novo Nordisk's ranking is a reflection of the company's inclusion of access to medicine within its core business, including equitable pricing strategies, local capability building and integrating philanthropy with business activities.

In 2013, Novo provided medical treatments for approximately 24.3 million people with diabetes worldwide, showing a 7% increase compared with 2012.

"Today, more than 80% of people with diabetes live in low- and middle-income countries where access to medicine and treatment is simply not adequate for the millions in need," says Lars Rebien Sørensen, chief executive officer at Novo Nordisk. "Last year, we launched our Strategy for Global Access to Diabetes Care strengthening our already existing efforts to break down barriers that inhibit access to care and help us reach 40 million people living with diabetes by 2020."

Since Novo Nordisk launched its first access to care strategy in 2001, diabetes has become a major global health challenge. There are now an estimated 387 million people worldwide with diabetes and the number is expected to rise to over half a billion by 2035.

Working towards sustainable solutions
The 2014 Access to Medicine Index highlighted two of the company's access to diabetes care initiatives - the Base of the Pyramid project and the Changing Diabetes® in Children programme. The Base of the Pyramid project takes an integrated approach together with faith-based organisations to improve diagnosis, treatment and diabetes education for the working poor in developing countries. The Changing Diabetes® in Children programme provides medicine free of cost, treatment and patient education for children living with type 1 diabetes in low-income countries.

"We have the knowledge, capabilities and commitment to improve the health of people living with diabetes regardless of where they live," says Lars Rebien Sørensen. "As the world leader in diabetes care, we will continue to work with governments, health organisations and communities to make this a reality across the globe."

About the Access to Medicine Index
The ranking of the 2014 Access to Medicine Index is based on measurements of 21 pharmaceutical companies' policies and practices in improving access to medicine across a specific range of countries, diseases and product types. The Access to Medicine Index is published every two years.

About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately 41,000 employees in 75 countries, and markets its products in more than 180 countries.

Most Popular Now

GSK reaches agreement with Novartis to acquire ful…

GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that it has reached an agreement with Novartis for the buyout of Novartis' 36.5% stake in their Consumer Healthcare Jo...

Canadian neuroscientists say daily ibuprofen can p…

A Vancouver-based research team led by Canada's most cited neuroscientist, Dr. Patrick McGeer, has successfully carried out studies suggesting that, if started early enou...

First proof a synthesized antibiotic is capable of…

A "game changing" new antibiotic which is capable of killing superbugs has been successfully synthesised and used to treat an infection for the first time - and could lea...

Merck partners with Medisafe to help improve medic…

Merck, a leading science and technology company, today announced a new collaboration with US-based Medisafe to help its cardiometabolic patients better manage medication ...

Phase III data in The Lancet show Novartis siponim…

Novartis today announced that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS) w...

Taking a standard prostate cancer drug with food b…

By taking a high-cost drug with a low-fat meal - instead of on an empty stomach, as prescribed - prostate cancer patients could decrease their daily dose, prevent digesti...

North and south cooperation to combat tuberculosis

Tuberculosis can be cured and could be eradicated. For this to happen, however, patients have to receive the right treatment. Researchers at the Makerere University and t...

Boehringer Ingelheim and OSE Immunotherapeutics an…

Boehringer Ingelheim and OSE Immunotherapeutics, a biotechnology company focused on the development of innovative immunotherapies, have announced a collaboration and excl...

New immunotherapy for lung cancer shows promise of…

In a groundbreaking development, results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at contro...

Personalized tumor vaccine shows promise in pilot …

A new type of cancer vaccine has yielded promising results in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and...

Lokelma approved in the EU for the treatment of ad…

AstraZeneca today announced that the European Commission has granted marketing authorisation for Lokelma (formerly ZS-9, sodium zirconium cyclosilicate) for the treatment...

New targeted therapy schedule could keep melanoma …

Skin melanoma, a particularly insidious cancer, accounts for the vast majority skin cancer deaths and is one of the most common cancers in people under 30. Treatment for ...